The results of our study seem to confirm the initial hypothesis that dapagliflosin, having a positive hemodynamic response in T2DM patients with HF, needs a surrogate biomarker with much better reproducibility than NT-proBNP. Here, NPPB is linked to type 2 diabetes mellitus.